Noretynodrel, or norethynodrel, sold under the brand name Enovid among others, is a progestin medication which was previously used in birth control pills and in the treatment of gynecological disorders but is now no longer marketed. It was available both alone and in combination with an estrogen. The medication is taken by mouth. Noretynodrel is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It is a relatively weak progestogen. The medication has weak estrogenic activity, no or only very weak androgenic activity, and no other important hormonal activity. It is a prodrug of various active metabolites in the body, such as norethisterone among others. Noretynodrel was introduced for medical use in 1957. It was specifically approved at this time in combination with mestranol for the treatment of gynecological and menstrual disorders. Subsequently, in 1960, this formulation was approved for use as a birth control pill. It was the first birth control pill to be introduced, and was followed by birth control pills containing norethisterone and other progestins shortly thereafter. Due to its nature as a relatively weak progestogen, noretynodrel is no longer used in medicine. As such, it is no longer marketed.
Medical uses Noretynodrel was formerly used in combination with the estrogen mestranol in the treatment of gynecological and menstrual disorders and as a combined birth control pill. It has also been used in the treatment of endometriosis at high dosages of 40 to 100 mg/day. The medication has been discontinued, and is no longer marketed or used medically.
Contraindications
No adverse effects have been observed in breastfeeding infants whose mothers were treated with noretynodrel. Because of this, the American Academy of Pediatrics has considered noretynodrel to be usually compatible with breastfeeding.
Side effects
There is a reported case of signs of masculinization in a female infant whose mother was treated with noretynodrel for threatened miscarriage during pregnancy.
Overdose
Interactions
Pharmacology
Pharmacodynamics
Noretynodrel has weak progestogenic activity, weak estrogenic activity, and no or only very weak androgenic activity. It is considered to be a prodrug, and for this reason, the metabolites of noretynodrel play an important role in its biological activity. As such, the pharmacodynamics of noretynodrel cannot be understood without reference to its metabolism. Noretynodrel is closely related to norethisterone and tibolone, which are the δ4-isomer and the 7α-methyl derivative of noretynodrel, respectively. It is metabolized in a very similar manner to tibolone, whereas the metabolism of norethisterone differs. Both noretynodrel and tibolone are transformed into 3α- and 3β-hydroxylated metabolites and a δ4-isomer metabolite (in the case of noretynodrel, this being norethisterone), whereas norethisterone is not 3α- or 3β-hydroxylated (and of course does not form a δ4-isomer metabolite). The major metabolites of noretynodrel are 3α-hydroxynoretynodrel and to a lesser extent 3β-hydroxynoretynodrel, formed respectively by 3α- and 3β-hydroxysteroid dehydrogenases (AKR1C1–4), while the δ4-isomer norethisterone is a minor metabolite formed in small amounts. Tibolone is considered to be a prodrug of both its 3α- and 3β-hydroxylated and δ4-isomerized metabolites. Noretynodrel is also thought to be a prodrug, as it is rapidly metabolized and cleared from circulation and shows very weak relative affinity for the progesterone receptor (PR), although it appears to form norethisterone in only minor quantities.
Progestogenic activity Noretynodrel is a relatively weak progestogen, with only about one-tenth of the progestogenic activity of norethisterone. The ovulation-inhibiting dosage of noretynodrel is 4.0 mg/day, relative to 0.4 mg/day in the case of norethisterone. Conversely, the endometrial transformation dosage of noretynodrel is 150 mg per cycle, relative to 120 mg per cycle for norethisterone. In terms of the PR, noretynodrel possesses only about 6 to 19% of the affinity of norethisterone for the PRA, whereas the affinity of the two drugs for the PRB is similar (noretynodrel possesses 94% of the affinity of norethisterone for the PRB). Tibolone and the δ4-isomer metabolite of tibolone have similar affinity for the PRs as noretynodrel and norethisterone, respectively, whereas the 3α- and 3β-hydroxylated metabolites of tibolone are virtually devoid of affinity for the PRs. Since the structurally related androgen/anabolic steroid trestolone (7α-methyl-19-nortestosterone) is known to be a potent progestogen, suggesting that a 7α-methyl substitution does not interfere with progestogenic activity, 3α- and 3β-hydroxynoretynodrel likely are devoid of affinity for the PR similarly to the 3α- and 3β-hydroxylated metabolites of tibolone.
Androgenic activity Noretynodrel has been said to possess no or only very weak androgenic activity. This is in contrast to norethisterone, which shows mild but significant androgenicity. Relative to norethisterone, noretynodrel has 45 to 81% lower affinity for the androgen receptor (AR). In accordance, no androgenic effects (such as hirsutism, clitoral enlargement, or voice changes) have been observed with noretynodrel even when used in large dosages (e.g., 60 mg/day) for prolonged periods of time (9–12 months) in the treatment of women with endometriosis. Additionally, noretynodrel has not been found to virilize female fetuses, in contrast to many other testosterone-derived progestins including ethisterone, norethisterone, and norethisterone acetate. However, at least one case of pseudohermaphroditism (virilized genitalia) has been observed that may have been due to noretynodrel. The δ4-isomer metabolite of tibolone shows dramatically and disproportionately increased affinity for the AR relative to norethisterone and noretynodrel (5.7- to 18.5-fold greater than that of norethisterone), indicating that the 7α-methyl group of tibolone markedly increases its androgenic activity and is responsible for the greater androgenic effects of tibolone relative to noretynodrel.
… excerpt ends here. Continue reading the full article.




